I
nflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is commonly diagnosed in adolescents or young adults, with around 1 in 4 patients receiving a diagnosis before the age of 20 years.
1 A significant increase in the incidence of IBD in the pediatric population has occurred over the last few decades, with rates varying across populations. 2 Pediatric-onset IBD typically presents with a more severe phenotype than adult-onset disease, and its symptoms may include growth retardation and delayed onset of puberty, in addition to age-independent symptoms such as abdominal pain, diarrhea, rectal bleeding, and weight loss. 1, 3 Early and effective treatment is therefore especially important in this group of vulnerable patients. 4, 5 Infliximab is an anti-tumor necrosis factor (anti-TNF) monoclonal antibody used in the treatment of pediatric CD and UC, usually after conventional therapies have failed. As with many biologics, the relatively high cost and patent expiry of infliximab has led to the development of less expensive biosimilar versions. CT-P13 (infliximab-dyyb; Remsima, Inflectra [CELLTRION, Incheon, Republic of Korea]) is a biosimilar of the infliximab reference product (RP; Remicade) that has been approved in countries worldwide for all indications held by the RP, including pediatric and adult CD and UC. In accordance with regulatory guidelines on biosimilars, 6, 7 approval of CT-P13 was based on extensive comparisons with the infliximab RP in nonclinical studies and 2 randomized controlled trials performed in adults with rheumatoid arthritis and
